Loading...
XNASCYTK
Market cap5.59bUSD
Jan 08, Last price  
47.37USD
1D
-2.35%
1Q
-10.87%
Jan 2017
289.88%
Name

Cytokinetics Inc

Chart & Performance

D1W1MN
XNAS:CYTK chart
P/E
—
P/S
742.41
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.14%
Rev. gr., 5y
-24.89%
Revenues
8m
-92.04%
13,442,0008,912,0003,127,00013,622,00012,420,00081,538,0002,577,0004,000,0007,559,00030,648,00046,940,00028,658,000106,407,00013,368,00031,501,00026,868,00055,828,00070,428,00094,588,0007,530,000
Net income
-526m
L+30.73%
-37,198,000-42,252,000-57,115,000-48,894,000-56,374,00024,544,000-49,287,000-47,860,000-39,015,000-33,717,000-14,646,000-37,501,00016,453,000-127,790,000-106,289,000-149,052,000-164,135,000-242,370,000-402,552,000-526,244,000
CFO
-414m
L+38.33%
-34,032,000-39,484,000-47,170,000-3,005,000-61,328,0008,416,000-44,830,000-45,595,000-33,438,000-7,718,000-44,843,0004,883,00036,982,000-101,759,000-101,215,000-90,907,0008,943,000-142,522,000-299,516,000-414,333,000
Earnings
Feb 25, 2025

Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
URL
https://cytokinetics.com/
IPO date
Apr 29, 2004
Employees
409
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,530
-92.04%
94,588
34.30%
Cost of revenue
503,735
425,378
Unusual Expense (Income)
NOPBT
(496,205)
(330,790)
NOPBT Margin
Operating Taxes
13,597
Tax Rate
NOPAT
(496,205)
(344,387)
Net income
(526,244)
30.73%
(402,552)
66.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
164,233
35,086
BB yield
-2.04%
-0.85%
Debt
Debt current
45,862
12,829
Long-term debt
866,118
876,237
Deferred revenue
Other long-term liabilities
380,161
301,545
Net debt
256,622
59,781
Cash flow
Cash from operating activities
(414,333)
(299,516)
CAPEX
(1,416)
(11,335)
Cash from investing activities
239,253
(262,134)
Cash from financing activities
221,317
516,166
FCF
(480,750)
(354,131)
Balance
Cash
614,824
782,577
Long term investments
40,534
46,708
Excess cash
654,982
824,556
Stockholders' equity
(2,112,146)
(1,589,490)
Invested Capital
2,879,646
2,532,477
ROIC
ROCE
EV
Common stock shares outstanding
96,524
89,825
Price
83.49
82.21%
45.82
0.53%
Market cap
8,058,789
95.80%
4,115,782
17.44%
EV
8,315,411
4,175,562
EBITDA
(484,313)
(324,976)
EV/EBITDA
Interest
57,668
51,156
Interest/NOPBT